GlassScriptPhysician profile
William Travis Cain
NPI 1821083973
$9,850.73
in general payments reported to CMS, 2019-2025
33 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $661 · 2021: $1,354 · 2022: $1,308 · 2023: $1,396 · 2024: $1,474 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498 · Education: $19.41 · Consulting Fee: $14.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,497.85 |
| Education | $19.41 |
| Consulting Fee | $14.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,686.33 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,192.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,083.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $621.00 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $521.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $512.00 | 2020-2025 | Dupixent |
| Pfizer INC. | $386.13 | 2019-2025 | |
| Genentech USA, INC. | $278.54 | 2020-2025 | Xolair |
| Optinose US, INC. | $276.59 | 2020-2025 | |
| Ars Pharmaceuticals Operations, INC. | $261.18 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $254.87 | 2020-2024 | Hyqvia, Eohilia |
| Octapharma USA, INC. | $233.53 | 2021-2025 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $232.12 | 2019-2021 | |
| Amgen INC. | $179.93 | 2021-2024 | Tezspire |
| Grifols USA, LLC | $167.50 | 2019-2025 | Xembify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $152.23 | 2019-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.86 | 2021-2024 | Spiriva Respimat, Stiolto Respimat |
| Hikma Pharmaceuticals USA | $101.62 | 2022-2025 | Ryaltris |
| Atricure, INC. | $100.11 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Biocryst US Sales Co., LLC | $85.19 | 2023-2025 | Orladeyo |
| Phathom Pharmaceuticals, INC. | $64.88 | 2025 | Voquezna |
| Mylan Specialty L.P. | $62.95 | 2020-2023 | Yupelri |
| Alk-Abello, INC | $53.02 | 2019-2022 | |
| Pharming Healthcare, INC. | $33.22 | 2021 | |
| Eyevance Pharmaceuticals LLC | $29.75 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $29.72 | 2025 | Sajazir |
| Azurity Pharmaceuticals, INC. | $21.98 | 2025 | Alvesco |
| Phadia US INC. | $20.96 | 2022 | |
| Shire North American Group INC | $20.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.19 | 2019 | |
| Ionis Pharmaceuticals, INC. | $17.52 | 2025 | |
| Blueprint Medicines Corporation | $17.00 | 2022 | |
| Adma Biomanufacturing LLC | $14.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.